Medexus Pharmaceuticals Inc. (TSE:MDP - Get Free Report) was up 1.6% during mid-day trading on Wednesday . The stock traded as high as C$2.51 and last traded at C$2.50. Approximately 33,700 shares traded hands during trading, a decline of 19% from the average daily volume of 41,850 shares. The stock had previously closed at C$2.46.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on MDP shares. Stifel Canada raised shares of Medexus Pharmaceuticals from a "moderate buy" rating to a "strong-buy" rating in a research report on Monday, August 12th. Stifel Nicolaus increased their price objective on shares of Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the company a "buy" rating in a research report on Thursday, August 22nd. Ventum Cap Mkts raised shares of Medexus Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, June 26th. Finally, Leede Financial set a C$8.25 price objective on shares of Medexus Pharmaceuticals and gave the company a "speculative buy" rating in a research report on Monday, September 30th.
Check Out Our Latest Analysis on MDP
Medexus Pharmaceuticals Price Performance
The company has a market capitalization of C$63.53 million, a P/E ratio of 51.80 and a beta of 1.96. The company's 50-day moving average price is C$2.55 and its two-hundred day moving average price is C$2.11.
Medexus Pharmaceuticals (TSE:MDP - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The company reported C$0.11 earnings per share for the quarter, topping the consensus estimate of C$0.04 by C$0.07. Medexus Pharmaceuticals had a net margin of 1.00% and a return on equity of 3.95%. The business had revenue of C$37.33 million during the quarter, compared to analysts' expectations of C$36.95 million. On average, analysts anticipate that Medexus Pharmaceuticals Inc. will post 0.1633166 earnings per share for the current fiscal year.
Medexus Pharmaceuticals Company Profile
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Featured Stories
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
